Expansion Blitz Masks Margin Squeeze; the Real Test is H2
PAT surged 56% year-over-year to ₹57 Cr, but quarter-on-quarter growth stalled at +3.3% despite 6.7% revenue growth. Greenfield losses of ₹42 Cr in the first half reveal the real unit economics story.
₹56.9 Cr
+55.8% YoY
₹655.5 Cr
+31.4% YoY
+3.3%
vs +6.7% revenue—margin compression signal
₹42 Cr
51 new facilities opened past 12 months
The headline reads like a breakout quarter. PAT grew 56%, revenue 31%, and management raised both facility guidance (60→65) and capex (₹400→500 Cr). But look at the quarter-on-quarter progression: PAT up just 3.3% despite 6.7% revenue growth. That's the real story—expansion is accelerating, but unit economics are compressing.
The Margin Squeeze
The culprit is greenfield ramp-up. Dr. Agarwal's opened 51 new surgical facilities in the past 12 months and absorbed cumulative losses of ₹42 Cr in H1 FY27 alone (₹18.2 Cr from FY27 vintage, ₹20.1 Cr from FY26 cohort). These centers are maturing—FY26 facilities grew 20.9%, FY25 reached 67.8%—but the burn is front-loaded. EBITDA margin held flat at 28.2%, but that's only because mature facilities (opened before FY23, contributing 75% of revenue) posted 17.2% organic growth. Strip out the mature base, and the new cohort is still underwater.
Claims vs. What Holds Up
Revenue rose 31.4% YoY to ₹655 Cr
PAT grew 55.8% YoY to ₹57 Cr
SSSG at 18.8% beats 12-16% guidance range
39 facilities delivered in H1 (tracking 65 FY27 target)
Greenfield playbook proven; FY25–FY26 cohorts ramping faster
Capex revision and margin stability justified
All major claims corroborated. Revenue, PAT, SSSG, and facility counts match the delivered result. The greenfield execution track is real—older cohorts do ramp. But the implication is understated on the call: new facilities are absorbing losses now, and H2 will add 26 more. That's not a small bet; it's half the annual target, all compressed into a 6-month window.
What Changed on This Call
The revised guidance is a vote of confidence backed by H1 execution (39 facilities landed). But it's also a test: 26 more centers in H2 is the highest velocity ever attempted. Capex raised to ₹500 Cr and finance costs already jumped to ₹46 Cr (from ₹37 Cr in Q1) due to the ₹55 Cr acquisition of Dr. Anchal Gupta's 2-center practice in Delhi. Debt is rising. The margin story depends entirely on ramp velocity.
Bull-Bear Ledger
Bull: Mature network (75% of revenue) growing 17.2% YoY; pricing power intact despite competitive entry
Bull: Greenfield playbook proven; older cohorts show strong ramp (FY25 67.8% growth, FY26 20.9% still early stage)
Bull: Surgical mix premiumization (30% high-end, Femto cataract +25.5% YoY) drives yield expansion
Bull: Pipeline visibility strong; 12-18 month advance planning, 100+ centers in early stages filtered to 65 target
Bear: QoQ PAT growth stalled at +3.3%; sequential deceleration signals near-term ceiling
Bear: Greenfield losses (₹42 Cr H1, ₹18.2 Cr expected H2) are material; if ramp slows, losses extend
Bear: Finance costs rising (₹46 Cr); ₹500 Cr capex may require more leverage
Bear: Regulatory headwinds (IOL pricing, drug scrutiny) deferred; near-term risk timing unclear
Risks, Ranked by Holder Impact
Greenfield execution misses H2 target (26 facilities)
Medium-HighGuidance assumes 26 of 65 FY27 total in 6 months. Slippage compresses annual run-rate and delays profitability. Investors pricing in this execution; miss triggers repricing.
Unit economics deteriorate as ramp velocity slows
Medium-High₹42 Cr H1 losses on 51 centers imply ~₹820 Cr per center. If new markets underperform utilization targets, loss absorption extends and margin pressure intensifies.
Capex and leverage spiral
Medium₹500 Cr capex + ₹55 Cr acquisition debt pushed finance costs to ₹46 Cr. Further capex may require more debt. Rising rates or covenant tightness could constrain expansion.
Regulatory headwind on IOL pricing or drug supply
MediumGovernment policy on intraocular lens markups and Sun Pharma halt cited but impact deferred. Cataract (73% of surgeries) reliant on IOL supply. Price controls or supply constraints could pressurize margins.
Competitive intensity in Tier-1 cities (South/West)
Low-MediumApollo, Narayana, Vision India entering. SSSG beat (17.8%) suggests pricing power intact, but margin compression risk in saturated micro-markets over medium term.
How the Market is Positioned
Dr. Agarwal's trades at ₹537, down 5.5% from its all-time high of ₹568, but still above the 20-day (₹490), 50-day (₹495), and 200-day (₹470) moving averages. The stock has run 34% off its 52-week low, and the market is clearly long. FII ownership holds steady at 58%—institutional conviction is high and stable (up 0.02pp QoQ). Bulk activity in August shows informed buying: ICICI Prudential, Polar Capital (Healthcare Opportunities), Invesco, and Allianz accumulated at ₹501–504. No meaningful insider or promoter selling is flagged.
The -5.5% drawdown from all-time high is modest given the margin-compression risk just revealed on the call. The market has priced in most of the facility expansion upside; the question now is whether the street believes the greenfield playbook holds at 55+ facilities per year. The modest pullback suggests yes, but valuation multiple offers limited margin of safety if H2 execution disappoints.
What to Watch Next
1 · H2 facility delivery pace
Did management land the 26-center target, or did execution slip? Monthly tracking will show whether the greenfield playbook holds at high velocity.
2 · Q3 sequential PAT growth
If QoQ growth rebounds to +6%+ despite more greenfield drag, it signals mature acceleration and mix shift are offsetting losses. Flat or negative growth confirms margin pressure is winning.
3 · FY28 guidance and greenfield loss path
When do cumulative greenfield losses peak and turn positive? FY27 H2 losses of ₹18+ Cr could push cumulative above ₹60 Cr by year-end. Clarify the loss tail and margin recovery timeline.
Dr. Agarwal's delivered on the headline numbers—56% PAT growth is real. But it masks a quarter-to-quarter deceleration that reveals the true tension: expansion is accelerating while unit economics compress. The company is betting that mature-market pricing power and surgical mix premiumization can absorb greenfield losses at a 65-facility-per-year run rate. So far, execution has been strong. But the sequential PAT slowdown says the margin offset isn't keeping pace. H2 will tell whether this is a temporary ramp effect or a structural change.
The stock trades near all-time highs with 58% FII ownership and institutional buying in recent weeks. Valuation offers limited cushion. For new entrants, wait for H2 delivery proof. For holders, the single number to track is Q3 QoQ PAT growth—if it rebounds to +5%+, the margin story stabilizes; if it stays flat or negative, the greenfield playbook needs repricing.
Informational and educational content only. Not investment advice.